New drug could help teens shed pounds
NCT ID NCT07255209
First seen Dec 08, 2025 · Last updated Jun 23, 2026 · Updated 28 times
Summary
This study tests a drug called IBI362 in 180 Chinese adolescents aged 12 to 17 who are obese or overweight and haven't lost enough weight with diet and exercise alone. Participants will receive either the drug or a placebo to see if it helps reduce body mass index (BMI) safely. The trial is double-blind, meaning neither the teens nor the doctors know who gets the real drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Children's Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310052, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBI362 (a drug for weight loss)
What this could lead to
If successful, this could provide a new medication option for adolescents struggling with obesity or overweight.
What could go wrong
This is an early-stage trial with a small number of participants, and results may not apply to all teens. The drug may cause side effects or not work better than placebo.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.